CCT3 CAR-T
EXUMA’s proprietary, centralized CCT3 CAR-T process is launch-ready and needs no further modifications to be commercially viable.
- A proprietary process which could support market entry
- 12-day vein-to-vein, fully closed, fresh in, frozen out process
- No manufacturing failures from IIT studies in China
- Uses real-time monitoring electronic batch record bar code system to help mitigate potential errors
rPOC SC CAR-T
Rapid Point-of-Care (rPOC) subcu (SC) could greatly expand access to a potentially life-saving CAR-T therapy while reducing costs by avoiding the need for adjuvant chemotherapy and shortening the hospital stay.
- A revolutionary process which could dramatically change the CAR-T landscape
- Subcutaneously injected CAR-T product never leaves the patient’s side and can be manufactured in less than six hrs
- Decreased complexity has potential for reduced cost and increases access
- Leverages existing oncology infusion clinic infrastructure